



(51) International Patent Classification:

A61K 9/08 (2006.01) A61K 47/18 (2017.01)
 A61B 5/00 (2006.01) A61K 47/10 (2017.01)
 A61K 31/404 (2006.01) A61K 47/20 (2006.01)
 A61K 47/22 (2006.01) A61K 49/00 (2006.01)
 A61K 41/00 (2020.01) A61K 47/26 (2006.01)
 A61K 47/02 (2006.01)

(21) International Application Number:

PCT/EP2022/056443

(22) International Filing Date:

14 March 2022 (14.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21305322.6 17 March 2021 (17.03.2021) EP

(71) Applicant: PROVEPHARM LIFE SOLUTIONS

[FR/FR]; Les Baronnie, 22 Rue Marc Donadille, 13013 Marseille (FR).

(72) Inventors: LAURENT, Marina; Provepharm Life Solutions,

22 rue Marc Donadille, Les Baronnie, 13013 Marseille (FR). SAYAH, Babak; Provepharm Life Solutions, 22 rue Marc Donadille, Les Baronnie, 13013 Marseille (FR). LOPEZ, Nicolas; Provepharm Life Solutions, 22 rue Marc Donadille, Les Baronnie, 13013 Marseille (FR).

(74) Agent: CORIZZI, Valérie; PACT-IP, 37 rue Royale, 92210 Saint-Cloud (FR).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
 — in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: STABLE FORMULATIONS OF INDOCYANINE GREEN

(57) Abstract: The invention relates to indocyanine green compositions with improved stability, especially improved storage stability. In particular, the invention relates to compositions comprising indocyanine green and at least one stabilizer chosen from ascorbic acid and salts thereof.

STABLE FORMULATIONS OF INDOCYANINE GREEN

The present invention relates to the field of medical and pharmaceutical arts. The invention relates to indocyanine green compositions with improved stability, especially improved storage stability. In particular, the invention relates to indocyanine green compositions comprising at least one stabilizer chosen from ascorbic acid and salts thereof. The present invention also relates to a method for preparing such compositions and methods for use thereof.

State of the art

Indocyanine green (ICG) is a water-soluble tricarbocyanine fluorescent dye approved by the United States Food and Drug Administration for medical diagnosis. It is used in determining hepatic function, cardiac output, liver blood flow, microcirculation of skin flaps and ophthalmic angiography. These medical uses of ICG are based on its high optical absorbance in a spectral region where human tissues are relatively transparent (750-800 nm). These medical uses are made possible due to its very low toxicity. After intravenous administration, ICG is fast extracted by the liver into bile juice, and has an effective half-life of about 3-4 minutes depending on the hepatic function.

For the above-mentioned applications, ICG has to be administered in the form of aqueous solutions. It is commercially available as a lyophilized powder that can be dissolved in sterile water for injection and is often supplied as a kit. However, ICG has a poor stability in aqueous environments and degrades quickly, which limits its usefulness in certain applications, including time-sensitive surgical procedures. The instructions of vendors of ICG range from immediate use of the reconstituted ICG solution up to usage within ten hours, with any unused portion being discarded.

Studies have shown that in aqueous media, ICG molecules undergo physicochemical transformations such as aggregation, especially at high concentrations. ICG in water readily forms dimers and oligomers while it remains monomeric in human plasma, methanol and dimethyl sulfoxide (DMSO) ^[1]. Also, singlet oxygen can be generated by ICG leading to dioxetanes that thermally decompose into several carbonyl compounds ^[2]. These decomposition products could reduce the viability of cells in vitro.

The physicochemical transformations of ICG occur more readily in response to light exposure, elevated temperatures and at high concentrations of ICG ^[3, 4, 5]. The type

and intensity of light to which ICG is exposed also affects the degradation. Physicochemical transformations result in the quick degradation of the optical properties of ICG, leading to a discoloration, a diminished fluorescence intensity, and a shift in peak absorbance. It has been reported that the absorbance of ICG at its spectral peak is
5 reduced by 10% after 10 hours of storage in water and direct light ^[4].

In an effort to overcome these shortcomings, many developments have been carried out to improve the stability of Indocyanine green in aqueous solutions.

Engel et al. reported that the chemical degradation of ICG can be inhibited by the addition of sodium azide NaN_3 , a quencher of singlet oxygen ^[2].

10 Mindt et al. investigated the stability of samples of ICG stored either in dark or in clear vials at different temperatures. The absorbance and fluorescence measurements show that, when stored at 4°C in the dark, ICG is stable for three days with 20% fluorescence intensity lost during this period. On the basis of these tests, it is suggested that ICG could be used for longer than one day after preparation from stock if the ICG
15 solution is stored at 4°C in the dark ^[6].

Other researchers have suggested encapsulating ICG into nanometer-sized carriers protecting the ICG molecule from degradation. For example, CN103301482 discloses tri-block polypeptide ICG loaded micelles comprising a polyleucine core, a polylysine middle layer and a polyethylene glycol shell, wherein indocyanine green is dispersed in
20 the core. The core-shell structure to wrap the indocyanine green makes it possible to effectively prevent ICG molecules from being aggregated, so that the stability of ICG is enhanced.

Kirchherr et al. discloses the encapsulation of ICG within Solutol HS15 (poly-oxyethylene esters of 12-hydroxystearic acid) micellar system. This formulation
25 exhibited lower aggregation behavior and high aqueous stability over 4 weeks compared to free ICG in aqueous solution ^[7].

US 6,944,493 discloses indocyanine green compositions exhibiting enhanced stability and enhanced indocyanine green concentration. The invention is based on indocyanine green liposomal formulations which are stable for at least 24 hours after
30 reconstitution. All the formulations disclosed in US 6,944,493 are reconstituted with a diluent solution comprising ethanol and polysorbate 80 among others.

WO2016/123864 discloses compositions comprising ICG embedded in the lipid membrane of a lipid nanoparticle. The nanoparticle has a fluorescence intensity between

4-and 5-fold higher than that of free ICG. After being stored at 4 °C, the nanoparticle has a fluorescence intensity between 4-and 100,000-fold higher than that of free ICG in aqueous solution for between 0 and 300 days.

5 Dedora et al. discloses the complexation of ICG with highly soluble methyl β -CyD and FDA-approved sulfobutyl ether β -CyD (Captisol ®) in aqueous solution. These complexes allow reducing the aggregation of ICG and exhibit sustained fluorescence increases over 24 hours of more than twice when compared with free ICG in water. However, it has been found that ICG complexed with methyl β -CyD severely reduced the viability of some fibroblasts [8].

10 The encapsulation or the complexation of ICG with the above systems present drawbacks such as incompatibility with the cells, or could limit the ability of the ICG molecules, once injected into the blood, to interact with plasma proteins, and therefore could potentially slow down the excretion kinetics from the vasculature.

15 WO2020/240514 discloses a formulation of indocyanine green comprising disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride. After reconstitution with an aqueous diluent, the solution is stable up to 24 hours.

US2010/0181535 discloses a method for enhancing the fluorescence intensity of a fluorescent dye, wherein a fluorescent dye is admixed with a redox buffer. The fluorescent dye can be selected from rhodamines, carborhodamines, oxazine dyes, and/or cyanine dyes including indocyanine green. The redox buffer comprises at least one reducing agent and/or at least one oxidizing agent and/or at least one reducing-oxidizing agent. Suitable reducing agents can be selected from the group comprising thiophenols, thionaphthols, phenolsulfide, uric acid, urea, bilirubin, ascorbic acid and/or flavine. Experiments in a single molecule fluorescence measurement showed that the addition of 1mM of ascorbic acid to a cyanine dye immobilized to DNA allows to extend the length of the dark state of the cyanine dye (i.e., the period of time, during which the fluorescent dye remains in the non-fluorescent state). On the other hand, the combined use of a reducing agent 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox®) and an oxidizing agent methylviologen with a cyanine dye in solution showed an improvement of the photostability up to 2.6 times in comparison with the solution of the fluorescent dye in phosphate buffered saline. These experiments are carried out by irradiating the dye with a laser activating signal in a fluorescence detecting instrument. The authors mention that another advantage of the use of the described redox buffer is

20
25
30

that the shelf life of the fluorescent dye solution containing it can be increased by 10% to 20% compared to the otherwise identical fluorescent dye solution without redox buffers. However, this document is silent with regards to the long-term storage stability of the compositions.

5 WO9423646 discloses storage stable compositions comprising voltage sensitive dyes for use as optical imaging contrast agents, in particular indocyanine green. The compositions comprise air protecting reagents to inhibit the decomposition of ICG such as antioxidants and surfactants. The air protecting reagents can be chosen from sodium sulfite, sodium ascorbate, glutathione, dithiothreitol, EDTA, polysorbate 80 and
10 carboxymethylcellulose. Decomposition of ICG, measured by decrease in the maximal absorbance in the UV-visible spectra between 600-900 nm, was inhibited in presence of air free compositions stored away from light. The best results reported in this document show a 30% decrease of the ICG content in one hour. When the experimental conditions of this document are reproduced, a rapid degradation of the composition is observed as
15 demonstrated in the experimental part of the present application

All of these prior arts report increasing the aqueous stability of ICG, but none provides an aqueous solution of ICG with a stability for a period of time superior to 1-3 days. Thus, a need exists for an ICG aqueous composition that exhibits stability exceeding those of the prior art formulations.

20 Some of the formulations of the prior art are prepared in expensive equipment, and/or require long manufacturing process times and/or specialized excipients. Some formulations require excipients like alcohol and polysorbate that make the injection of the ICG composition painful and challenging.

In particular, there was a need for an ICG aqueous composition that is stable at
25 room temperature, for periods of time of one or several months.

There was also a need for ICG compositions for intravenous administration that are compatible with target tissues, non-toxic and whose metabolic elimination is rapid.

The invention aims at providing storage stable ICG compositions that are simple to formulate and are based on easily accessible material, and with ICG concentration
30 sufficient to be used in the same manner as prior art short shelf-life ICG formulations.

It has been surprisingly found a formulation of ICG comprising a compound chosen from ascorbic acid or a salt thereof showing improved stability when compared with prior art compositions.

The formulations according to the invention comprise ICG at concentrations comparable or superior to those of the prior art. They can be formulated as a lyophilized powder or as an aqueous solution. They have an improved storage stability and shelf life in comparison with those of the prior art.

5 It is also an aim of the invention to provide formulations that are stable, cost effective and are easy to manufacture. It is an aim of the invention to provide formulations that do not cause any discomfort to the patient at the time of administration.

Summary of the invention

10 The invention relates to a composition comprising indocyanine green (a) and a compound (b) chosen from ascorbic acid, its salts, and mixtures thereof, wherein the drop in content of indocyanine green in the composition measured in % area by HPLC at 240 nm is less than or equal to 10%, when the composition is stored at ambient temperature for at least 1 month.

15 Advantageously, the content of ICG in the composition of the invention prior to storage is greater than or equal to 90%, the content of indocyanine green being measured as % area by HPLC at 240 nm.

Preferably, the total amount of impurities in the ICG composition prior to storage, measured as area % by HPLC at 240 nm, is less than or equal to 10%.

20 Preferably, the increase of impurities in the composition according to the invention as area % variation measured by HPLC at 240 nm is less than or equal to 10%, when the composition is stored for at least 1 month at ambient temperature.

25 The invention also relates to an aqueous composition comprising at least indocyanine green (a) and a compound (b) chosen from ascorbic acid, its salts, and mixtures thereof, wherein the weight ratio of compound (b)/indocyanine green (a) ranges from 0.15 to 30 and the concentration of indocyanine green in the aqueous composition is comprised between 0.1 and 50 mg/ml, preferably between 0.1 and 30 mg/ml.

Advantageously, the weight ratio of compound (b) to indocyanine green (a) ranges from 0.15 to 25, preferably from 0.15 to 20.

30 Advantageously, the weight ratio of compound (b) to indocyanine green (a) ranges from 0.15 to 15.

According to an embodiment, the compound (b) is ascorbic acid.

According to another embodiment, the compound (b) is a salt of ascorbic acid.

Preferably, according to this embodiment, the compound (b) is chosen from sodium ascorbate, potassium ascorbate, calcium ascorbate, magnesium ascorbate, and mixtures thereof. Preferably, according to this embodiment, the compound (b) is sodium ascorbate.

5 Optionally, the indocyanine green composition according to the invention further comprises at least one compound (c) chosen from ethylenediaminetetraacetic acid (EDTA), D-alpha-tocopherol polyethylene glycol 1000 succinate (Vitamin E-TPGS), thiomalic acid, isosorbide, PEG 400, PEG 1000, thioglycolic acid, thiourea, alpha and beta cyclodextrin, thiolactic acid, glutathione reduced, thioglycerol, sorbitol, 10 methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

Preferably, the compound (c) is chosen from glutathione reduced, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

Preferably, the weight ratio of compound (c) to indocyanine green (a) ranges from 15 1:500 to 100:1, preferably from 1:100 to 10:1, more preferably from 1:100 to 4:1.

According to an embodiment, the composition according to the invention comprises up to 5% by weight of sodium iodide based on the weight of indocyanine green.

Preferably, the concentration of indocyanine green in the aqueous composition is 20 comprised between 1 and 25 mg/ml.

According to a preferred embodiment, the aqueous indocyanine green composition according to the invention is packed in a vial or an ampoule.

The invention also relates to an aqueous composition comprising indocyanine green (a) and a compound (b) chosen from ascorbic acid, its salts, and mixtures thereof, 25 wherein the weight ratio of the compound (b)/indocyanine green (a) is between 0.15 and 30 and the concentration of indocyanine green in the aqueous composition is comprised between 0.1 and 50 mg/ml, preferably between 0.1 and 30 mg/ml, for its use as a medicament or a diagnostic agent.

The invention also relates to a kit comprising in separate compartments at least 1/ 30 a lyophilized powder of the composition as defined above and in details here-under, and 2/ an aqueous diluent.

The invention also relates to a kit capable to be used for the preparation of an aqueous composition according to the invention, comprising in separate compartments

at least 1/indocyanine green (a) and 2/ an aqueous solution comprising at least a compound (b) selected from ascorbic acid, its salts, and mixtures thereof.

The invention also relates to a method of diagnosis and/or therapy in a patient comprising the administration in an effective amount, in particular by intravenous route,
5 of an aqueous composition according to the invention.

Detailed description

The term "consists essentially of" followed by one or more characteristics, means that may be included in the process or the material of the invention, besides explicitly listed components or steps, components or steps that do not materially affect the
10 properties and characteristics of the invention.

The expression "comprised between X and Y" includes boundaries, unless explicitly stated otherwise. This expression means that the target range includes the X and Y values, and all values from X to Y.

The references to methods of treatment in the description can be interpreted as
15 references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for the treatment of the human (or animal) body by therapy or for diagnosis.

The stability of indocyanine green composition according to the invention

The present invention is intended to provide a composition of indocyanine green
20 with improved stability compared to prior art compositions.

The terms "stable composition" and "stability" refer to a composition wherein the indocyanine green content remains stable upon storage during a certain amount of time (for example 1 week, 1 month, 2 months, 6 months, 1 year, 2 years, etc....).

The stability of the composition is evaluated by measuring the variation of
25 indocyanine green content in the composition after storage during extended periods of time.

Preferably, the compositions according to the invention are advantageous in that they show substantially no signs of aggregation, degradation, precipitation and substantially no, or minimal, formation of impurities as a result of chemical modification
30 of the indocyanine green after storage during extended periods of time. In addition, the compositions according to the invention are advantageous in that they show no significant discoloration or decrease in fluorescence intensity or in peak absorbance after storage during extended periods of time.

In particular, the present invention provides a composition comprising indocyanine green that exhibits improved stability as compared to presently available indocyanine green formulations.

Advantageously, the composition according to the invention exhibits a stability of
5 at least 10, and more preferably at least 30, more preferably at least 50, more preferably still 100 times relative to the currently-approved indocyanine green formulations.

In one aspect, the composition according to the invention is stable when stored at ambient temperature for at least one month, preferably for at least 3 months, more preferably for at least 6 months, still more preferably for at least 12 months and most
10 preferably for at least 2 years.

The term “ambient temperature” means a controlled room temperature as between 20 to 25 °C, with excursions between 15 to 30 °C, as defined by the United States Pharmacopeia, or between 15 to 25 °C as defined by the European Pharmacopoeia.

Preferably, the composition according to the invention is stable at ambient
15 temperature over a period of time ranging from 1 month to 3 years, preferably over a period ranging from 3 month to 3 years, more preferably over a period ranging from 1 year to 3 years, still more preferably over a period ranging from 1 year to 2 years at ambient temperature.

Advantageously, the composition according to the invention is stable when stored
20 in a container protecting it from natural light and/or UV light and/or fluorescent light for at least one month, preferably for at least 3 months, more preferably for at least 6 months, and most preferably for at least 2 years.

A container capable of protecting the composition from natural light and/or UV light and/or fluorescent light is a container the walls of which have a maximum
25 percentage of light transmission at any wavelength of at least 50%. Typically, the container can be an opaque or amber-colored container and/or an opaque secondary packaging component (e.g., carton or overwrap).

Advantageously, the composition according to the invention is stable when stored in a tightly closed or hermetically closed container for at least one month, preferably for
30 at least 3 months, more preferably for at least 6 months, and most preferably for at least 2 years.

The stability of the composition according to the invention can be evaluated by visual inspection of color and/or transparency and/or other analytical methods.

The analytical methods for evaluating the stability of the composition are known by the person skilled in the art. They can include nuclear magnetic resonance (NMR), high-performance liquid chromatography (HPLC), size exclusion chromatography (SEC), liquid chromatography coupled with mass spectrometric analysis (LC-MS),
5 dynamic light scattering (DLS), differential scanning calorimetry (DSC), UV spectroscopy, and Fourier-transform infrared spectroscopy (FTIR) or a combination of these methods.

Advantageously, the stability of the composition is evaluated by measuring the variation of indocyanine green content in the composition by HPLC before and after
10 storage during extended periods of time. More advantageously, the ICG content in the composition and the variation of this content is evaluated in % area by HPLC at 240 nm.

Preferably, the stability of the inventive composition corresponds to a drop in content of indocyanine green in the composition measured in % area by HPLC at 240 nm of less than or equal to 10%, when the composition is stored at ambient temperature
15 for at least 1 month, preferably 3 months, more preferably 6 months, still more preferably 12 months and most preferably for at least 2 years.

Preferably, evidence of the stability of the inventive composition corresponds to a drop in content of indocyanine green in the composition measured in % area by HPLC at 240 nm of less than or equal to 5%, when the composition is stored at ambient
20 temperature for at least 1 month, preferably 3 months, more preferably 6 months, still more preferably 12 months and most preferably for at least 2 years.

Even more preferably, evidence of the stability of the inventive composition corresponds to a drop in content of indocyanine green in the composition measured in % area by HPLC at 240 nm of less than or equal to 2%, when the composition is stored
25 at ambient temperature for at least 1 month, preferably 3 months, more preferably 6 months, still more preferably 12 months and most preferably for at least 2 years.

By “drop in content” it is to be understood, within the meaning of the present application, the percentage difference between the measured content of ICG in the composition prior to storage and the measured content of ICG in the composition after
30 a determined storage time, the content being measured in % area by HPLC at 240 nm.

Preferably, the measured content of ICG in the composition prior to storage is greater than or equal to 90%, preferably greater than or equal to 95%, more preferably

greater than or equal to 97%, most preferably greater or equal to 99%, the content of indocyanine green being measured as % area by HPLC at 240 nm.

Stability of the indocyanine green inventive composition may also correspond to the fact that the total amount of impurities contained in the inventive composition does not increase during storage, in particular does not increase to a level that reduces the capability of the indocyanine green composition to be used for medical and/or diagnostic applications.

For example, when the composition is stored at ambient temperature for at least 1 month and such impurities are then measured by HPLC, only a small amount of the impurities in the composition is observed and this amount does not increase considerably over time.

The term “impurity” is to be understood, within the context of the present invention, as a chemical entity that is not indocyanine green, or excipients or other additives to the indocyanine green inventive composition.

The impurities may be process-related impurities such as byproducts or intermediates that can be formed during the manufacture of the indocyanine green, or degradation related impurities that result from chemical transformation of indocyanine green during storage. Degradation related impurities are products that may be formed during storage, for example in response to light exposure, temperature, and humidity, or reaction with oxygen.

In an embodiment, the increase of impurities in the composition according to the invention as area % variation measured by HPLC at 240 nm is less than or equal to 10%, preferably less than or equal to 5%, more preferably less than or equal to 2% when the composition is stored for at least 1 month, preferably 2 months, more preferably 6 months, most preferably for at least 2 years at ambient temperature.

In an embodiment, the total amount of impurities in the ICG composition prior to storage, measured as area % by HPLC at 240 nm, is less than or equal to 10%, preferably less than or equal to 5%, more preferably less than or equal to 1%.

The term “total amount of impurities” includes process related impurities and degradation related impurities as described above.


The composition of indocyanine green

The invention provides a composition comprising indocyanine green (a) and at least one stabilizing compound (b) selected from ascorbic acid and salts thereof.

Optionally, the composition according to the invention may comprise at least one additional compound (c) different from the compound (b).

The indocyanine green (a)

The term indocyanine green refers to indocyanine green as well as pharmaceutically acceptable salts, solvates, hydrates, acids, anhydrous and free base forms thereof, preferably it refers to indocyanine green.



Indocyanine green (CAS N°: 3599-32-4)

Indocyanine green can be prepared by any process known to those skilled in the art. For example, indocyanine green can be prepared according to the process described in WO95/07888 or WO2017093889. Preferably, the indocyanine green preparation process involves a step of purification of the obtained product.

Advantageously, the indocyanine green used in the composition according to the invention is substantially pure. Preferably, the indocyanine green used in the composition according to the invention is provided as a composition with a purity greater than 90.0%, preferably greater than 95.0 %, more preferably greater than 97.0%, still more preferably, greater than 99.7% as measured by HPLC.

The term “purity” used herein means the extent to which the raw material indocyanine green is free from undesirable or adulterating chemical entities.

According to the invention, purity and impurities in the indocyanine green material are evaluated in % area by HPLC at 240 nm.

Preferably, the indocyanine green used in the composition according to the invention is provided as a composition comprising less than 5.0 %, preferably less than 1.0 %, more preferably less than 0.5 % of impurities as measured by HPLC.

Preferably, the indocyanine green used in the composition according to the invention is provided as a composition comprising less than 0.50%, preferably less than 0.40%, more preferably less than 0.20%, most preferably less than 0.15% of each impurity as measured by HPLC.

The impurities contained in the indocyanine green can be any reaction by-product or intermediate resulting from the process of manufacture. For example, as described in the document US2019/0337896, the impurities can include N-phenylacetamide, 4-(1,1,2-trimethyl-1H-benzo[e]indolium-3-yl) butane-1-sulfonate, 4-(1,1,2-dimethyl-2-
5 ((1E, 3E, 5E)-6-(N-phenylacetamido) hexa-1,3,5-trienyl)-1H-benzo[e]indolium-3-yl) butane-1-sulfonate, but are not limited thereto.

Preferably, the indocyanine green is provided as a composition comprising a content of metallic contaminants of less than 200 ppm, preferably, less than 100 ppm, more preferably less than 50 ppm, even more preferably less than 20 ppm, by weight of
10 metals based on weight of indocyanine green. The metallic contaminant content in the indocyanine green can be measured by Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

By "metallic contaminants" it is to be understood the so-called "heavy" metals and in particular: Al, As, Cd, Cr, Cu, Fe, Sn, Mn, Hg, Mo, Ni, Pb, Zn as well as their organic
15 and inorganic derivatives.

Still more preferably, the indocyanine green comprises no or less than 2 ppm of lead and Arsenic.

The indocyanine green used in the composition of the invention is provided as a composition that can also comprise sodium iodide. The sodium iodide is an additive
20 often present in indocyanine green commercial compositions. When present, the iodide content is desirably limited to less than 5% by weight based on the weight of indocyanine green. The sodium iodide content in the indocyanine green can be measured by potentiometry.

The indocyanine green used in the composition of the invention may be provided
25 in any suitable form such as a lyophilizate or a crystalline powder.

The stabilizing compound (b)

The compound (b) can be selected from ascorbic acid, also known as (5R)-5-[(1S)-1,2-Dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one, 3-Oxo-L-gulofuranolactone, L-ascorbic acid or vitamin C, salts of ascorbic acid and mixtures thereof.

30 By "mixtures thereof" is meant the mixtures of ascorbic acid and salts of ascorbic acid in all proportions.

Salts of ascorbic acid may include, non limitatively, sodium ascorbate, potassium ascorbate, calcium ascorbate, and magnesium ascorbate.

According to a first embodiment of the invention, the compound (b) is ascorbic acid.

According to a second embodiment of the invention, the compound (b) is a salt of ascorbic acid.

5 Preferably, according to this embodiment, the compound (b) is sodium ascorbate.

According to a third embodiment, the composition comprises indocyanine green, ascorbic acid and at least one salt of ascorbic acid, preferably sodium ascorbate.

The inventors have surprisingly observed an enhanced stability of the indocyanine green composition in an aqueous medium, when the compound (b) is associated to
10 indocyanine green (a).

In a preferred embodiment, the weight ratio of compound (b) to indocyanine green (a) ranges from 0.15 to 30, preferably from 0.15 to 25, preferably from 0.15 to 20, preferably from 0.15 to 15, more preferably from 0.20 to 15, still more preferably from 0.20 to 13.

15 In a preferred embodiment, the molar ratio of compound (b) to indocyanine green (a) ranges from 0.30 to 120, preferably from 0.30 to 60, more preferably from 0.40 to 60, still more preferably, from 0.40 to 55.

In a favorite embodiment of the present invention, the composition consists essentially of indocyanine green (a) and at least one compound (b) selected from
20 ascorbic acid, salts thereof and mixtures thereof.

In another favorite embodiment of the present invention, the composition consists essentially of indocyanine green (a), at least one compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, and further comprising iodide.

According to another aspect, the present invention relates to the use of ascorbic
25 acid and/or salts thereof to improve the storage stability of ICG compositions.

The compound (c)

In another embodiment of the present invention, the composition may further comprise one or more compounds (c) selected from those known by the skilled person to be suitable for medical and/or diagnosis injectable solutions.

30 When present, the compound (c) may be, for example, selected from ethylenediaminetetraacetic acid (EDTA), D-alpha-tocopherol polyethylene glycol 1000 succinate (Vitamin E-TPGS), thiomalic acid, isosorbide, PEG 400, PEG 1000, thioglycolic acid, thiourea, alpha and beta cyclodextrin, thiolactic acid, glutathione

reduced, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

Preferably, the compound (c) may be selected from glutathione reduced, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

By " mixtures thereof" is meant the mixtures of two or more of glutathione reduced, thioglycerol, sorbitol, methionine, sodium chloride histidine and dithiothreitol (DTT) in all proportions.

Preferably, the weight ratio of compound (c) to indocyanine green (a) ranges from 1:500 to 100:1, preferably from 1:500 to 10:1, more preferably from 1:100 to 10:1, most preferably from 1:100 to 4:1.

Preferably, the weight ratio of compound (c) to compound (b) ranges from 1:100 to 100:1, preferably from 1:10 to 10:1.

When present, the compound (c) may be provided in any form such as solid, liquid, or semi-solid. It may be also in the form of an aqueous solution.

In a favorite embodiment of the present invention, the composition consists essentially of indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, and a compound (c) selected from reduced glutathione, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

In another favorite embodiment of the present invention, the composition consists essentially of indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, iodide and a compound (c) selected from reduced glutathione, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

Other additives

The composition according to the invention may further comprise at least one pharmaceutically acceptable additive.

As used herein, the term "pharmaceutically acceptable" refers to compounds, materials and compositions which are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The term "additives" include components contained in the composition other than the ingredients a), b) and c) as defined above or sodium iodide. Examples of such additives include buffer agents, such as for example phosphate buffers, pH adjusting agents, isotonizing agents, surfactants, antiseptic agents, tonicifying agents, antimicrobial agents, wetting agents, and emulsifiers.

For example, the composition of the invention may include one or more additive selected from the group comprising sodium hydroxide, potassium hydroxide, methylparaben, propylparaben, sodium acetate, sodium citrate, sodium carbonate, ammonium carbonate, sodium bicarbonate, benzoate, acetate, boric acid, lactic acid, glutaric acid, malic acid, succinic acid and carbonic acid, as well as alkali or alkaline earth salts of these acids, meglumine, hydrochloric acid, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, citric acid, lactic acid, phosphoric acid, sulfuric acid, arginine, alanine, glycine and lysine.

These additives are generally available to one of ordinary skill in the art and may be in any form such as solid, liquid, or semi-solid.

Preferably, the amount of additives in the composition of the invention is within a range that does not substantially adversely affect the activity of the indocyanine green. Preferably, the composition of the invention contains the minimum number and amount of additives necessary to provide a stable and efficacious composition.

Form of the composition according to the invention

The composition according to the invention may be provided in any suitable form, but is preferably provided in the form of an aqueous composition or a lyophilized solid composition.

Aqueous composition

According to a first aspect, the composition according to the invention is in the form of an aqueous composition.

By "aqueous composition" it is to be understood an aqueous solution, an aqueous suspension, a colloidal aqueous suspension, an aqueous dispersion, preferably an aqueous solution.

The term "aqueous solution" means a composition of indocyanine green as described above, the ingredients of which are soluble in an aqueous medium.

Advantageously, according to this variant, the composition comprises an aqueous diluent, indocyanine green (a), one or more compounds (b) as defined above, optionally

one or more compounds (c) as defined above and optionally one or more pharmaceutically acceptable additive.

5 The aqueous diluent is a pharmaceutically acceptable solvent, that is safe and nontoxic upon administration to humans or animals, and is useful for the preparation of a pharmaceutical formulation.

The aqueous diluent includes water and may include one or more pharmaceutically acceptable additive. In some variants of the method disclosed hereunder, one or more compounds (b) as defined above, optionally one or more compounds (c) as defined above are introduced into the aqueous diluent before mixing with the ICG.
10 In such embodiments, one or more compounds (b), optionally one or more compounds (c) may be considered as part of the aqueous diluent.

An appropriate aqueous diluent can be any liquid which is biologically acceptable and in which the composition of the invention is completely soluble. Water, particularly sterile water for injection (SWFI) and/or bacteriostatic water for injection (BWFI), is a preferred diluent, since it does not include salts or other compounds which may affect the stability of the ICG. However, another aqueous diluent may be used such as a sterile saline solution, Ringer's solution, dextrose solution, phosphate-buffered saline (PBS) solution, glucose solution and the like. The aqueous diluent may also comprise buffers, bacteriostats and solutes which render the composition isotonic with the blood of the
15
20 intended recipient.

According to an embodiment, the aqueous diluent is chosen from the group consisting of water for injection, bacteriostatic water for injection, sterile saline solution, Ringer's solution, dextrose solution, phosphate-buffered saline solution and glucose solution.

25 The person skilled in the art is able to choose the diluent according to the desired use and with respect to the other compounds of the composition. He is also able to adjust the amounts of the excipients according to their solubility in the aqueous solution.

In a preferred embodiment, the aqueous diluent is water for injection, particularly sterile water for injection (SWFI) and/or bacteriostatic water for injection (BWFI).

30 Advantageously, the aqueous solution has an osmolarity of at least 1 mOsM. More advantageously, the aqueous solution has an osmolarity comprised between 1 and 300 mOsM, more preferably between 1 and 200 mOsM.

The concentration of indocyanine green in the aqueous composition of the invention can be any concentration that is appropriate for use in medical treatment or diagnostics, in particular to produce angiographic images of satisfactory quality.

According to a favorite embodiment, the aqueous composition according to the invention has a concentration of indocyanine green comprised between 0.1 mg/ml and 50 mg/ml.

When the ICG solution is of a concentration of less than 0.1 mg/ml, fluorescence is not sufficient for satisfactory detection by analytical instruments.

According to a favorite embodiment, the aqueous composition according to the invention has a concentration of indocyanine green comprised between 0.1 and 30 mg/ml, preferably comprised between 1 and 25 mg/ml, more preferably between 1 and 10 mg/ml.

In the case where one or more constituents of the composition of the invention such as compound (b) or possibly compound (c) are added as an aqueous solution, the volume of aqueous diluent can be adjusted to obtain the desired concentration of ICG.

In an embodiment of the present invention, the aqueous composition consists essentially of an aqueous diluent, indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof.

In an embodiment of the present invention, the aqueous composition consists essentially of an aqueous diluent, indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, and iodide.

In another embodiment, the aqueous composition consists essentially of an aqueous diluent, indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, and a compound (c) selected from reduced glutathione, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.

In another embodiment, the aqueous composition consists essentially of an aqueous diluent, indocyanine green (a), a stabilizing compound (b) selected from ascorbic acid, salts thereof and mixtures thereof, and a compound (c) selected from reduced glutathione, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof, and iodide.

The favorite percentages of compounds (ICG (a), stabilizing compound (b), and compound (c)) in the aqueous composition are the same as expressed above in the chapter "The Indocyanine Green composition".

Lyophilized solid composition

5 According to another favorite embodiment, the composition according to the invention is in the form of a lyophilized composition or a lyophilized powder.

The term "lyophilized composition ", "lyophilized powder " or "lyophilizate" refers to the solid composition according to the invention obtained by lyophilization of an aqueous solution.

10 The term "lyophilization", or "lyophilized," refers to a process by which the composition in an aqueous solvent is first frozen and then the frozen solvent is removed by sublimation in a vacuum environment.

When provided as a lyophilizate, the composition according to the invention can be transformed into a solution prior to administration by use of an aqueous diluent as described therein. The reconstituted aqueous solution, also a composition according to the invention, is then stable at ambient temperature for at least 1 month, preferably 2 months, more preferably 6 months, most preferably for at least 2 years.

15 All limitations described above regarding the aqueous diluent, ICG concentrations, pH, osmolarity and stability also apply for the aqueous solution reconstituted from the lyophilized composition according to the invention.

20 Further, in an embodiment, the lyophilized composition according to the invention has a short reconstitution time of less than 2 minutes, preferably less than 1 minute, and is suitable for intravenous administration after dilution with an aqueous diluent.

By "reconstitution time" it is meant the time required to rehydrate the lyophilized composition with an aqueous solution to a particle-free clarified solution.

25 After the composition has been reconstituted as an aqueous solution for medical or diagnosis use, preferably, the solution is stored in a container that protects it from light and oxygen.

Kits

30 According to a favorite embodiment, the invention relates to a kit comprising in a first part the composition according to the invention in the form of a lyophilized powder, and in a second part an aqueous diluent.

According to another favorite embodiment, the invention relates to a kit comprising in a first part indocyanine green (a), and in a second part an aqueous solution comprising at least a stabilizing compound (b) selected from ascorbic acid and its salts. Optionally the aqueous solution can comprise a compound (c) as defined above, and
5 optionally one or more additives as described above.

According to this embodiment, the indocyanine green is preferably in the form of lyophilizate powder.

All the preferred embodiments described above for the ICG composition and the aqueous diluent apply also to any of the kit variants.

10 According to an embodiment, the kit according to the invention is composed of parts (powder and diluent) in amounts such that the aqueous solution reconstituted from the kit has an ICG concentration ranging from 0.1 to 50 mg/ml, preferably from 0.1 to 30 mg/ml, more preferably comprised between 1 and 25 mg/ml, and most preferably between 1 and 10 mg/ml.

15 According to these favorite embodiments, the kit comprises at least two separate compartments where the lyophilized powder and the aqueous diluent are stored separately.

The kit can comprise two separate vials, packaged with or without a syringe, or it can comprise a pre-filled two-compartment syringe, like for example a dual-chamber by-pass syringe.
20

Such a kit permits mixing the powder and the aqueous solution before administration.

The kits according to one or the other variant, are intended to be used to reconstitute extemporaneously a stable aqueous solution of indocyanine green as described therein. They have the advantage of providing the essential components of the composition for injection in optimized storage conditions and in appropriate amounts to provide the desired concentration. Thus, the aqueous composition can be reconstituted without dilution by a diluent in addition to the diluent contained in the kit. Thanks to this packaging as a kit, dosing errors, or the introduction of contaminants, may be
25
30 avoided.

Method of preparation of the composition according to the invention

The composition according to the invention may be prepared using any known method, and is not limited to specific methods.

For example, the composition may be prepared by mixing the indocyanine green (a) with the stabilizing compound (b), and optionally with one or more compounds (c) as described above, and optionally one or more pharmaceutically acceptable excipients.

Preferably, the mixing of the ingredients of the composition according to the invention is carried out in an aqueous solvent as described above. The order of addition of the components constituting the composition according to the invention may vary. For example, indocyanine green may be solubilized in the aqueous diluent and the stabilizing compound (b) and optionally the compound (c) and additives can be added afterwards. The compounds (b) and (c) can be mixed prior to their addition to the solubilized indocyanine green. Alternately, indocyanine green can be introduced into an aqueous solution wherein compound (b) and optionally compound(s) (c) have been previously solubilized.

Preferably, mixing is carried out under inert atmosphere such as under an argon or a nitrogen atmosphere. The aqueous diluent and/or liquid ingredients are preferably degassed before use.

When provided as a lyophilizate, the lyophilization of the composition according to the invention can be carried out using standard equipment for lyophilization or vacuum drying. The cycle of lyophilization may be varied depending on the equipment and facilities used which can be adjusted by those skilled in the art.

The pre-lyophilization aqueous solution is preferably the aqueous solution of indocyanine green as described above. This pre-lyophilization aqueous solution according to the invention can be sterilized prior to lyophilization. The sterilization is generally achieved by filtration of the solution through an appropriate membrane.

Preferably the aqueous solution is lyophilized in a short delay after its preparation in order to prevent any degradation of the composition. The lyophilizate can be stored for months before use. Preferably the lyophilizate is stored in conditions wherein it is protected from air and/or humidity and/or light.

When provided as an aqueous composition, the indocyanine green composition according to the invention can be also reconstituted by use of the lyophilizate and the aqueous diluent from the kits described above. To carry out the reconstitution, the lyophilizate composition may be introduced into a vial, with the aqueous diluent being added thereafter.

The composition prepared in a lyophilized or aqueous form is advantageously placed in an airtight sealed container protected from light immediately after its preparation. The container may be for example a bottle, an ampoule, a vial, a syringe, or a tube. The container may be formed for example of glass, a polymer, a metal, or the like. The container may be a single-dose or multi-dose container.

In a favorite embodiment of the present invention, the container is preferably tinted glass vials or tinted glass ampoules. Advantageously, it is selected from tinted glass vials having vacuum headspaces or tinted glass ampoules. Preferably, the composition according to the invention is stored in tinted glass ampoules.

Advantageously, the composition according to the invention is stored at ambient temperature.

Uses of the compositions according to the invention

The compositions of the present invention may be used in a method of diagnosis and/or therapy (as a treatment agent) in a patient. The method comprises the administration of an aqueous solution according to the invention in an effective amount. This administration may be carried out by enteral route, parenteral route, in particular intravenous injection or by local application. Preferably, administration is carried out by intravenous injection.

The term "effective amount" means that amount of indocyanine green that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.

Advantageously, the compositions of the present invention can be used in a method of diagnosis and/or therapy as described above wherein the aqueous ICG composition is administered to the patient after at least 1 month, preferably after at least 6 months, more preferably after at least 12 months and most preferably after at least 2 years, from its preparation or reconstitution from the one of the kits as described above.

In particular, the composition according to the invention can be used in hyperthermal therapy, selective photocoagulation reinforced by ICG, photodynamic therapy (PDT), photodynamic and hyperthermal therapy (PHT). More particularly, as PDT applications, the composition according to the invention can be used for infection treatment, acne treatment, macular surgery, cancer treatment, etc. The use of the composition according to the invention may be associated with other therapies such as immunotherapy, radiotherapy, ultrasound and chemotherapy.

The composition according to the invention can also be used for obtaining an angiographic image of tissue in a patient, for determining cardiac output, for determining hepatic function and liver blood flow, for the diagnosis and treatment of age-related macular degeneration, of related choroidal neovascularization and tumors.

5 The compositions according to the invention are based on components which have been tested clinically and approved for administration to humans and/or animals.

For diagnosis applications, the amount of ICG composition administered to a patient should be sufficient to permit the dye to fluoresce when irradiated at the appropriate wavelength, knowing that the peak absorption and emission of ICG lies in
10 the range of 800-850 nm. The same standard is applicable to the therapeutic methods using ICG solution; sufficient dye should be administered to enable the treatment to be efficient. The amounts of ICG composition for administration may be readily determined by those skilled in the art, and should be at least the concentration currently accepted for use in ophthalmic angiography, e.g., for diagnosis, 2 ml of a 20 mg/mL
15 ICG solution. As acknowledged by the skilled professional, higher dye concentrations may advantageously be used in any of these diagnostic and treatment methods.

The improved stability of ICG in the solutions according to the invention provides improved diagnosis/treatment of the patient with the same amount of injected compounds, in comparison with prior art ICG compositions. This is made possible
20 because the improved stability of ICG will provide a more intense response to fluorescence irradiation.

Examples

I- Materials and methods:

1. Reagents and chemicals:

25 Indocyanine green was supplied by Biophore India Pharmaceuticals and used without further purification. Ascorbic acid was provided by Fisher Scientific. Sodium ascorbate was provided by Aldrich. The other reagents were purchased from Aldrich and used without further purification.

2. Equipment:

30 The stability of formulations in the foregoing examples was determined by high pressure liquid chromatography (HPLC). The equipment used to perform the analysis was an Agilent Infinity 1260 HPLC/MS system equipped with a diode array detector (UV-visible), Waters Xbridge Shield RP18- 4.6x100-5 μ m column and a MS ESI

spectrometer. The injected volume of solution was 5 μ L. Flow rate was 1 ml/min, column temperature was 30 °C, and detection was at 240 nm.

The elution is carried out by gradient. The mobile phase consists of a mixture of ammonium acetate/acetic acid buffer 10mM pH 5.5 (eluent A) and Acetonitrile (eluent B). The composition of the mobile phase was modified continuously during the elution process according to the following Table I:

Table I

Time (min)	Eluent A%	Eluent B%
0.0	85	15
3.0	85	15
40.0	30	70
40.1	85	15
47.0	85	15

3. Sample preparation:

To prepare the ICG formulations below, a quantity of stabilizing compound (b) and optionally one or more compounds (c) is weighed into a type I clear glass vial. The vial is then tared and 25 mg of indocyanine green is weighed into the vial. The vial is closed with a bromobutyl rubber stopper (from VWS) and then purged with a flow of nitrogen.

10 ml of WFI previously degassed are then added with a syringe. The vials are gently agitated manually until the solubility of the solutes is reached. The vials are then stored at room temperature and away from light.

II- Compositions comprising indocyanine green (a) and a stabilizing compound (b) according to the invention:

Table II

	C1	C2	C3*	C30	C31
ICG (mg)	25	25	25	100	250
Ascorbic acid (mg)	10				
Sodium ascorbate (mg)		10	10	25	100
Weight ratio ascorbic acid or sodium ascorbate/ICG	0.4	0.4	0.4	0.25	0.4
Concentration of ICG (mg/ml)	2.5	2.5	2.5	10	25
Storage stability					
% ICG area before storage (i)	99.07	99.70	99.48	99.48	99.48
Storage duration (weeks)	1	6	10 days	6	6
% ICG area after storage (f)	98.25	99.63	99.11	98.49	98.58
Variation (i-f) in %	0.82	0.07	0.37	0.99	0.90

*Composition C3 was prepared according to the same protocol as above in 10 ml of phosphate-buffered saline solution.

Table III below shows the variation of the stability over several months of an ICG composition comprising 25 mg of ICG and 10 mg of sodium ascorbate (concentration of ICG = 2.5 mg/ml, weight ratio sodium ascorbate/ICG = 0.4).

Table III

C32						
% ICG area before storage (i) = 99.48						
Storage stability						
Storage duration (months)	1	2	3	4	5	6.5
% ICG area after storage (f)	99.30	99.25	99.26	99.25	99.15	99.18
Variation (i-f) in %	0.18	0.23	0.22	0.23	0.33	0.30

The results given in Table II and Table III show that in the presence of ascorbic acid or sodium ascorbate, the ICG does not degrade in the aqueous solution and remains stable over time.

III- Compositions comprising indocyanine green (a), a stabilizing compound (b) and an additional compound (c) according to the invention:

Table IV

		C4	C5	C6	C7	C8	C9	C10	C11	C33	C34
ICG (mg)		25	25	25	25	25	25	25	25	25	25
Sodium ascorbate (mg)		10	10	10	10	10	10	10	10	10	10
Compound (c)	Glutathione reduced (mg)	1									
	Thioglycerol (mg)		1							1	
	Sorbitol (mg)			5							
	Methionine (mg)				5	5					
	NaCl (mg)					45	45	45		45	45
	Histidine (mg)							5			5
	DTT (mg)								4		
Weight ratio sodium ascorbate/ICG		0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Weight ratio compound (c)/ICG		0.04	0.04	0.2	0.2	2	1.8	2	0.16	0.04	2
Concentration of ICG (mg/ml)		2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
Storage stability											
% ICG area before storage (i)		99.70	99.70	99.70	99.70	99.07	99.70	99.70	99.70	99.48	99.48
Storage duration (weeks)		5	6	6	6	12	7	6	5	26	26
% ICG area after storage (f)		99.01	99.47	99.44	99.46	98.72	99.63	99.66	99.51	99.14	99.17
Variation (i-f) in %		0.69	0.23	0.26	0.24	0.35	0.07	0.04	0.19	0.34	0.31

To prepare solutions comprising sodium chloride, the quantities of ICG, compound (b) and methionine or histidine (compositions C8 and C10) are weighed into the vial, the vial is closed with the bromobutyl rubber stopper and then purged with a flow of nitrogen. 5 ml of degassed WFI and 5 ml of a 0.9% NaCl degassed solution were then added. The composition C9 is prepared according to the same protocol without methionine or histidine.

The results reported in Table IV show that aqueous indocyanine green compositions comprising sodium ascorbate and one or more additional compounds (c) selected from glutathione reduced, thioglycerol, sorbitol, methionine, sodium chloride, histidine, or DTT are also stable over time. Compounds (c) of Table IV do not significantly affect the stability of the ICG composition comprising a stabilizing compound (b) according to the invention.

IV- Effect of compound (b)/indocyanine green (a) ratio variation:

Table V

		C12	C13	C2	C14	C15	C16	C17
ICG (mg)		25	25	25	25	25	25	25
Sodium ascorbate (mg)		0.275	5	10	20	25	288	2500
Compound (c)	NaCl (mg)		45		45			
	Glutathione reduced (mg)				1			
	Methionine (mg)		5					
Weight ratio sodium ascorbate/ICG		0.11	0.2	0.4	0.8	1	11.5	100
Weight ratio compound (c)/ICG			2		1.84			
Concentration of ICG (mg/ml)		2.5	2.5	2.5	2.5	2.5	2.5	2.5
Storage stability								
% ICG area before storage (i)		99.48	99.70	99.70	99.70	99.48	99.70	99.70
Storage duration (weeks)		10 days	6	6	6	6	6	*
% ICG area after storage (f)		67.19	99.56	99.63	99.68	98.86	99.64	*
Variation (i-f) in %		32.29	0.14	0.07	0.02	0.62	0.06	*

* the solution is unclear; a precipitation of the solutes is observed.

V- Comparative compositions:

Composition C18 was prepared according to the protocol of §I-3.

Composition C19 was prepared according to the following protocol: 1.0 mg of ICG is weighted and added to 250 ml of phosphate buffer solution (pH 7.41). Then, 3 ml of a 0.0002 M sodium ascorbate solution were added. The solutions used to prepare this composition have been degassed before use. The obtained ICG solution was stored at room temperature away from light. This composition is according to the example 7 of the prior art WO9423646.

Composition C20 was prepared according to the following protocol: 2.5 mg of ICG are weighted and added to 250 ml of phosphate buffer solution (pH 7.41). 1.5 ml of this ICG/phosphate buffer solution were combined with 1.5 ml of a 0.10 M ascorbate solution. The solutions used to prepare this composition have been degassed before use. The obtained ICG solution was stored at room temperature away from light. This composition is according to the example 8 of the prior art WO9423646.

Table VI

	C18	C19	C20
ICG (mg)	1	1	0.015
Sodium ascorbate (mg)	0.4	0.11	29
Weight ratio sodium ascorbate/ICG	0.4	0.11	1933
Concentration of ICG (mg/ml)	3.9×10^{-3}	3.9×10^{-3}	5×10^{-3}
Storage stability			
% ICG area before storage (i)	99.48	99.70	99.70
Storage duration (days)	10	10	10
% ICG area after storage (f)	12.43	32.86	***
Variation (i-f) in %	87.05	66.84	***

*** The ICG content cannot be measured by HPLC because the sodium ascorbate peak is too much higher than the ICG peak. After 10 days of storage, the colour of the solution changed from light green to yellow.

The results of Table VI show that at very low concentrations of ICG, the ICG solutions are not storage stable, even if the weight ratio sodium ascorbate/ICG is within the range 0.15 to 30.

Table VII

		C21	C22	C23	C24	C25	C26	C27
ICG (mg)		25	25	25	25	25	25	25
Compound (c)	Glutathione reduced (mg)	1						
	Thioglycerol (mg)		1					
	Sorbitol (mg)			5				
	Methionine (mg)				5			
	NaCl (mg)					45		
Other compounds	Trolox (mg)						10	288
	Methylviologen (mg)							0.31
Phosphate-Buffered Saline pH = 7,4 (ml)							10	10
Weight ratio compound (c) or other compounds /ICG		0.04	0.04	0.2	0.2	1.8	0.4	11.53
Concentration of ICG (mg/ml)		2.5	2.5	2.5	2.5	2.5	2.5	2.5
Storage stability								
% ICG area before storage (i)		99.70	99.70	99.70	99.70	99.70	99.70	99.70
Storage duration (weeks)		6	6	6	6	5 days	-	**
% ICG area after storage (f)		13.34	66.24	61.69	40.76	89.54	-	**
Variation (i-f) in %		86.36	33.46	38.01	58.94	9.53	-	**

** the solution is unclear, the Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) is not soluble at this concentration.

Composition C25 was prepared by weighing the amount of ICG in the vial, the vial is closed with the bromobutyl rubber stopper and then purged with a flow of nitrogen. 5 ml of degassed WFI and 5 ml of a 0.9% NaCl degassed solution were then added.

Compositions C26 and C27 were prepared by weighing the amount of ICG and the additional compound(s) in the vial, the vial is closed with the bromobutyl rubber stopper and then purged with a flow of nitrogen. 10 ml of phosphate-buffered saline solution were then added.

The results of Table VII show that the content of ICG in the aqueous solutions varies considerably within a short delay in the absence of stabilizer compound (b) and solutions are not stable in the presence of compound (c) alone.

BIBLIOGRAPHY

- [1] Holzer W, Mauerer M, Penzkofer A, Szeimies RM, Abels C, Landthaler M, Bäumler W. Photostability and thermal stability of indocyanine green. J Photochem Photobiol B. 1998 Dec; 47(2-3):155-64.
- [2] Engel E, Schraml R, Maisch T, Kobuch K, König B, Szeimies RM, Hillenkamp J, Bäumler W, Vasold R. Light-induced decomposition of indocyanine green. Invest Ophthalmol Vis Sci. 2008 May; 49(5):1777-83.
- [3] Saxena V, Sadoqi M, Shao J. Degradation kinetics of indocyanine green in aqueous solution. J Pharm Sci. 2003 Oct; 92(10):2090-7.
- [4] Gathje J, Steuer RR, Nicholes KR. Stability studies on indocyanine green dye. J Appl Physiol. 1970 Aug; 29(2):181-5.
- [5] Barbier f, Deweerdt ga. Chromatography and I.R. spectrography of indocyanine green. Clin Chim Acta. 1964 Dec; 10:549-54.
- [6] Mindt S, Karampinis I, John M, Neumaier M, Nowak K. Stability and degradation of indocyanine green in plasma, aqueous solution and whole blood. Photochem Photobiol Sci. 2018 Sep 12; 17(9):1189-1196.
- [7] Kirchherr AK, Briel A, Mäder K. Stabilization of indocyanine green by encapsulation within micellar systems. Mol Pharm. 2009 Mar-Apr;6(2):480-91.
- [8] DeDora DJ, Suhrland C, Goenka S, Mullick Chowdhury S, Lalwani G, Mujica-Parodi LR, Sitharaman B. Sulfobutyl ether β -cyclodextrin (Captisol®) and methyl β -cyclodextrin enhance and stabilize fluorescence of aqueous indocyanine green. J Biomed Mater Res B Appl Biomater. 2016 Oct; 104(7):1457-64.

CLAIMS

1. An aqueous composition comprising at least indocyanine green (a) and a compound (b) chosen from ascorbic acid, its salts, and mixtures thereof, wherein the weight ratio of compound (b)/indocyanine green (a) ranges from 0.15 to 30 and the concentration of indocyanine green in the aqueous composition is comprised between 0.1 and 30 mg/ml.
2. The indocyanine green composition as claimed in claim 1, wherein the weight ratio of compound (b) to indocyanine green (a) ranges from 0.15 to 15.
3. The indocyanine green composition as claimed in claim 1 or claim 2, wherein the compound (b) is ascorbic acid.
4. The indocyanine green composition as claimed in claim 1 or claim 2, wherein the compound b) is a salt of ascorbic acid.
5. The indocyanine green composition as claimed in claim 4 wherein the compound (b) is chosen from sodium ascorbate, potassium ascorbate, calcium ascorbate, magnesium ascorbate, and mixtures thereof, preferably sodium ascorbate.
6. The indocyanine green composition as claimed in claims 1 to 5 further comprising at least one compound (c) chosen from glutathione reduced, thioglycerol, sorbitol, methionine, sodium chloride, histidine, dithiothreitol (DTT) and mixtures thereof.
7. The indocyanine green composition as claimed in claim 6, wherein the weight ratio of compound (c) to indocyanine green (a) ranges from 1:500 to 100:1, preferably from 1:100 to 10:1, more preferably from 1:100 to 4:1.
8. The indocyanine green composition as claimed in anyone of the preceding claims, wherein it comprises up to 5% weight by weight sodium iodide based on the weight of indocyanine green.

9. The indocyanine green composition as claimed in anyone of the preceding claims, wherein the concentration of indocyanine green in the aqueous composition is comprised between 1 and 25 mg/ml.

5

10. The aqueous composition as claimed in anyone of the preceding claims, wherein the content of ICG in the composition prior to storage is greater than or equal to 90%, the content of indocyanine green being measured as % area by HPLC at 240 nm.

10

11. The indocyanine green composition as claimed in anyone of the preceding claims, for its use as a medicament or a diagnostic agent.

12. A kit comprising in separate compartments at least 1/ a lyophilized powder of the composition as defined in anyone of claims 1 to 10, and 2/ an aqueous diluent.

15

13. A kit capable to be used for the preparation of a composition according to anyone of claims 1 to 10, comprising in separate compartments at least 1/indocyanine green (a) and 2/ an aqueous solution comprising at least a compound (b) selected from ascorbic acid, its salts, and mixtures thereof.

20

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2022/056443

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A61K9/08	A61B5/00
	A61K47/02	A61K47/18
	A61K47/26	
	A61K31/404	A61K47/22
	A61K47/10	A61K47/20
		A61K41/00
		A61K49/00
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K A61B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94/23646 A1 (MALLINCKRODT MEDICAL INC [US]) 27 October 1994 (1994-10-27) the whole document page 14; example 8 -----	1-13
Y	WO 2020/240514 A1 (LEIUTIS PHARMACEUTICALS PVT LTD [IN]) 3 December 2020 (2020-12-03) the whole document page 6; example 1 -----	1-13
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 27 June 2022		Date of mailing of the international search report 07/07/2022
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Raposo, Antonio

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/056443

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9423646	A1	27-10-1994	AU 6707694 A	08-11-1994
			EP 0695138 A1	07-02-1996
			JP H08509260 A	01-10-1996
			MX PA94002884 A	18-06-2002
			WO 9423646 A1	27-10-1994

WO 2020240514	A1	03-12-2020	NONE	
